Catalog Number: 11044-1, 11044-2 Amount: 50μg/50μl, 100μg/100μl Swiss-Prot No. :P42224 Form of Antibody: Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl,0.02% sodium azide and 50% glycerol. Storage/Stability: Store at -20℃/1 year Immunogen: The antiserum was produced against synthesized phosphopeptide derived from human STAT1 around the phosphorylation site of tyrosine 701 (T-G-YP-I-K). Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site. Specificity/Sensitivity: STAT1 (phospho-Tyr701) antibody detects endogenous levels of STAT1 only when phosphorylated at tyrosine 701 Reactivity: Human,Mouse,Rat Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using STAT1 (phospho-Tyr701) antibody (#11044). Background : Signal transducer and activator of transcription that mediates signaling by IFNs. Following type I IFN (IFN-a and IFN-beta) binding to cell surface receptors, Jak kinases (TYK2 and JAK1) are activated, leading to tyrosine phosphorylation of STAT1 and STAT2. The phosphorylated STATs dimerize, associate with ISGF3G/IRF-9 to form a complex termed ISGF3 transcription factor, that enters the nucleus. ISGF3 binds to the IFN stimulated response element (ISRE) to activate the transcription of stimulated genes, which drive the cell in an antiviral state. In response to type II IFN (IFN-gamma), STAT1 is tyrosine- and serine-phosphorylated. It then forms a homodimer termed IFN-gamma-activated factor (GAF), migrates into the nucleus and binds to the IFN gamma activated sequence (GAS) to drive the expression of the target genes, inducing a cellular antiviral state.